Ali Azizi

Ali Azizi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ali Azizi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Ashkan Golshani

    Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada

    1 shared publication
  • Ashok Kumar

    Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Rd., Ottawa, Ontario, Canada K1H 8L1

    1 shared publication
  • Catalina Soare

    Infectious Disease and Vaccine Research Centre, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON, K1H 8L1, Canada

    1 shared publication
  • Francisco Diaz-Mitoma

    Department of Pathology and Laboratory Medicine, University of Ottawa, 451 Smyth Rd., Ottawa, Ontario, Canada K1H 8M5

    1 shared publication
  • Francisco Diaz-Mitoma

    VBI Vaccines Inc., Cambridge, MA, United States

    1 shared publication
  • Haitham Ghunaim

    Department of Pathology and Laboratory Medicine, University of Ottawa, 451 Smyth Rd., Ottawa, Ontario, Canada K1H 8M5

    1 shared publication

Latest Publications

  • Open Access

    Chemical-genetic profile analysis of five inhibitory compounds in yeast

    by Md Alamgir, Veronika Erukova, Matthew Jessulat, Ali Azizi, Ashkan Golshani

    Background: Chemical-genetic profiling of inhibitory compounds can lead to identification of their modes of action. These profiles can help elucidate the complex interactions between small bioactive compounds and the cell machinery, and explain putative gene function(s). Results: Colony size reduction was used to investigate the chemical-genetic profile of cycloheximide, 3-amino-1,2,4-triazole, paromomycin, streptomycin and neomycin in the yeast Saccharomyces cerevisiae. These compounds target the process of protein biosynthesis. More than 70,000 strains were analyzed from the array of gene deletion mutant yeast strains. As expected, the overall profiles of the tested compounds were similar, with deletions for genes involved in protein biosynthesis being the major category followed by metabolism. This implies that novel genes involved in protein biosynthesis could be identified from these profiles. Further investigations were carried out to assess the activity of three profiled genes in the process of protein biosynthesis using relative fitness of double mutants and other genetic assays. Conclusion: Chemical-genetic profiles provide insight into the molecular mechanism(s) of the examined compounds by elucidating their potential primary and secondary cellular target sites. Our follow-up investigations into the activity of three profiled genes in the process of protein biosynthesis provided further evidence concerning the usefulness of chemical-genetic analyses for annotating gene functions. We termed these genes TAE2, TAE3 and TAE4 for translation associated elements 2-4.


  • Open Access

    A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses

    by Ali Azizi, Susan Aucoin, Helina Tadesse, Rita Frost, Masoud Ghorbani, Catalina Soare, Turaya Naas, Francisco Diaz-Mitoma

    Several studies have shown that cell-mediated immune responses play a crucial role in controlling viral replication. As such, a candidate SARS vaccine should elicit broad CD8+ T-cell immune responses. Several groups of mice were immunized alone or in combination with SARS-nucleocapsid immunogen. A high level of specific SARS-CD8+ T-cell response was demonstrated in mice that received DNA encoding the SARS-nucleocapsid, protein and XIAP as an adjuvant. We also observed that co-administration of a plasmid expressing nucleocapsid, recombinant protein and montanide/CpG induces high antibody titers in immunized mice. Moreover, this vaccine approach merits further investigation as a potential candidate vaccine against SARS.